There is one clinical trial.
The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or matching placebo tablets to be administered orally for 10 days. Local supportive standard of care (SOC) will be allowed for all subjects. Efficacy and safety observations will be compared for treatment with active AT-527 tablets + SOC vs. placebo tablets + SOC.
Description: Respiratory failure defined as requirement for intubated mechanical ventilation.
Measure: Proportions (active vs. placebo) of subjects who progress to respiratory failure Time: Day 14 and Follow-up Day 14Description: Clinical recovery defined as time from start of treatment until normal body temperature and respiratory rate (<20 breaths per minute), with sufficient alleviation of other signs and symptoms to support discharge
Measure: Time to clinical recovery Time: Day 14